• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down 0.26% Nasdaq Down 0.18%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    70.75 Down 0.81(1.13%) 4:00PM EDT
    |After Hours : 70.75 0.00 (0.00%) 4:24PM EDT
    Prev Close:71.56
    Open:71.32
    Bid:70.55 x 100
    Ask:78.00 x 100
    1y Target Est:118.58
    Beta:1.89635
    Earnings Date:Nov 7 - Nov 11 (Est.)
    Day's Range:70.28 - 73.28
    52wk Range:49.96 - 110.75
    Volume:512,896
    Avg Vol (3m):830,056
    Market Cap:6.06B
    P/E (ttm):N/A
    EPS (ttm):-4.24
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Headlines

    » More Headlines for ALNY

    Comparison

    Symbol% ChgMkt Cap
    ALNYDown 1.13%6.06B
    PFEDown 0.66%211.57B
    MRKDown 0.48%173.41B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):204.97
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-16) :-4.64
    Quarterly EPS Est (Sep-16) :-1.15
    Mean Recommendation*:1.9
    PEG Ratio (5 yr expected):-0.33

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback